Capital Santé -Vitalité Globale
Food supplement declared in France, decision dated 22 July 2025
Capital Santé -Vitalité Globale (Forté Pharma) is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: resvératrol 10 mg per day, ubiquinone 10 mg per day, Camellia sinensis 150 mg per day, Ginkgo biloba 120 mg per day, Zingiber officinale 30 mg per day. 3 rules of use apply to its ingredients (limits and warnings).
- Brand
- Forté Pharma
- Food business operator placing the product on the market
- Laboratoire FORTE PHARMA SA
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Powder
- Daily dose
- 1 cuillère par jour
- Directions for use
- Prélever 1 cuillère doseuse remplie à ras bord et dissoudre dans un grand verre d'eau (200 ml ) ou shaker.
- Intended populations
- Men and women aged 18 and over
- Not recommended (according to the manufacturer)
- Femmes allaitantes, Autre : Vitalité- Soutien global de l'organisme, Femmes enceintes, Sous anticoagulants, Sous antidépresseurs, Sous antidiabétiques
- Objectives stated by the manufacturer (these are not authorised claims)
- Antioxydant, Articulations, Autre : Vitalité- Soutien global de l'organisme, Mémoire, Œil / Vision, Peau
- Flavourings
- Orange- Passion
Declaration 334798, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Camellia sinensis (L.) Kuntze | Feuille | Extrait sec aqueux | 150 mg |
| Ginkgo biloba L. | Feuille | Extrait sec hydroalcoolique | 120 mg |
| Zingiber officinale Roscoe | Rhizome | Extrait sec aqueux | 30 mg |
Substances
| Name | Per day |
|---|---|
| resvératrol | 10 mg |
| ubiquinone | 10 mg |
Other active ingredients
| Name | Per day |
|---|---|
| Collagène marin | not declared |
| Inuline | not declared |
Vitamins and minerals
Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).
| Declared form | Nutrient | EFSA limit, adults | Maximum dose in France |
|---|---|---|---|
| D-pantothenate, calcium | Pantothenic acid (vitamin B5) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| D-biotin | Biotin (vitamin B8) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| calcium salts of citric acid | Calcium | 2,500 mg | 800 mg |
| Chlorure de chrome | Chromium | no limit (insufficient data) | 25 µg |
| cupric gluconate | Copper | 5,000 µg | 2,000 µg |
| pteroylmonoglutamic acid | Folate (vitamin B9) | 1,000 µg | 200 µg |
| potassium iodide | Iodine | 600 µg | 150 µg |
| magnesium salts of citric acid | Magnesium | 250 mg | 300 mg |
| manganese gluconate | Manganese | 8 mg (safe level) | 3.5 mg |
| Molybdate de sodium | Molybdenum | 600 µg | 150 µg |
| nicotinamide | Nicotinamide (vitamin B3) | 900 mg | 54 mg |
| potassium salts of orthophosphoric acid | Phosphorus | no limit (insufficient data) | 450 mg |
| sodium selenate | Selenium | 255 µg | 50 µg |
| retinyl acetate | Vitamin A | 3,000 µg d'équivalent rétinol | 800 µg |
| thiamin hydrochloride | Vitamin B1 (thiamine) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| cyanocobalamin | Vitamin B12 | no adverse effect defined | dose annulled by the French Council of State in 2011 |
| riboflavin | Vitamin B2 (riboflavin) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| pyridoxine hydrochloride | Vitamin B6 | 12 mg | 2 mg |
| L-ascorbic acid | Vitamin C | no limit (insufficient data) | 180 mg |
| cholecalciferol | Vitamin D | 100 µg (4,000 IU) | 5 µg (200 IU) |
| DL-alpha-tocopheryl acetate | Vitamin E | 300 mg | 30 mg |
| menaquinone | Vitamin K | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| zinc gluconate | Zinc | 25 mg | 15 mg |
Additives
E950, E955, E160a, E330
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Has the product changed? Photograph the packaging.
Label warnings
Contient de la caféine (9 mg maximum par dose journalière) et de l’EGCG (22,5 mg maximum par dose journalière), déconseillé aux femmes enceintes ou qui allaitent et aux enfants de moins de 18 ans. Déconseillé aux femmes enceintes ou désireuses de l’être, ainsi qu'aux femme ménopausées (vitamine A). Contient du thé vert, déconseillé en cas d’ulcère gastro-duodénal, de troubles cardiaques, ou d’hyperthyroïdie. Ne doit pas être consommé si vous prenez le même jour d’autres produits contenant du thé vert. Ne doit pas être consommé à jeun. Ne pas consommer 800 mg ou plus d’épigallocatéchine-3-gallate (EGCG) par jour. L’emploi chez les personnes sous antidiabétique et sous traitement antidépresseur est déconseillé. Déconseillé en cas d’obstruction biliaire ou d’autres troubles de la fonction biliaire. Réservé à l’adulte. Ne convient pas aux personnes traitées aux anticoagulants coumariniques (vitamine K). Déconseillé en cas d’épilepsie ou en cas d’acte interventionnel invasif programmé. Déconseillé en cas de prises de médicaments anticoagulants et antiagrégants plaquettaires. En cas de traitements médicamenteux, demander conseil à un professionnel de santé. Ne pas utiliser en cas de sensibilité à l’iode ou de troubles de la thyroïde (apporte au maximum 50 μg par dose journalière). Ce complément alimentaire n’est pas un médicament.
Regulatory points
- Conditions légales
Contains tea (Camellia sinensis). Green tea extracts must provide less than 800 mg of epigallocatechin-3-gallate per daily portion, with mandatory warnings.
Source: Regulation (EC) No 1925/2006, latest consolidated version, annexe III, partie B (règlement (UE) 2022/2340).
- Conditions légales
Ginkgo biloba L.: L'étiquetage des compléments alimentaires qui contiennent la feuille de la plante Ginkgo biloba L. doit comporter un avertissement avec la teneur suivante: "Consultez votre médecin en cas de prise simultanée d'anticoagulants."
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
- Conditions légales
Camellia sinensis (L.) Kuntze: Seules sont admises la poudre issue du broyage des feuilles et les préparations obtenues à partir des solvants suivants : l'eau, l'alcool à 25 % (v/v), ainsi que les solvants autorisés pour la décaféination ou la suppression des matières irritantes et amères. Les recommandations d'emploi ne doivent pas conduire à une ingestion quotidienne d'EGCG supérieure à 300 mg. L'étiquetage doit comporter des avertissements déconseillant leur prise en dehors des repas, ainsi que leur consommation par les enfants, les adolescents, les femmes enceintes ou allaitantes.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Ginkgo biloba L.
Read the warning, when it applies and the studies cited
GINKGO - GINKGO BILOBA
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Blumenthal et al. 2000; WHO 1999).
Sources cited by Health Canada (3)
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Newton (MA): Integrative Medicine Communications; 2000.
- WHO 1999: World Health Organization. WHO monographs on selected medicinal plants, Volume 1. Geneva (CHE): World Health Organization; 1999.
- OMS 1999 : Organisation mondiale de la santé (OMS). Monographs on selected medicinal plants, Volume 1. Genève (CHE): Organisation mondiale de la santé; 1999.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking diabetes, high blood pressure or seizure medications (Brinker 2010).
Sources cited by Health Canada (1)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
Contraindications
Do not use if you are having a surgery (Gardner and McGuffin 2013).
Sources cited by Health Canada (1)
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.
Do not use if you are taking blood thinners or other health products that affect blood coagulation (Gardner and McGuffin 2013; Brinker 2010; Bent 2005).
Sources cited by Health Canada (3)
- Bent S, Goldberg H, Padula A, Avins AL. Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature. Journal of General Internal Medicine 2005;20(7):657-661. PubMed Systematic review
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.
- Zingiber officinale Roscoe
Read the warning, when it applies and the studies cited
GINGER - ZINGIBER OFFICINALE
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
- ubiquinone
Read the warning, when it applies and the studies cited
Coenzyme Q10 (UBIQUINONE-10)
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Rosenfeldt et al. 2007; Singh et al. 1999).
Sources cited by Health Canada (2)
- Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analysis
- Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Randomised trial
Applies to products providing more than 100 mg of Coenzyme Q10 per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).
Sources cited by Health Canada (3)
- Engelsen J, Nielsen JD, Hansen KF. [Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial]. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
- Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
- Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report
Condition of application: Migraine prophylaxis/prevention.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Brand : Forté Pharma
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Capital Santé -Vitalité Globale (Forté Pharma): composition and regulation”, https://compoatlas.com/en/supplements/products/334798-capital-sante-vitalite-globale, updated 15 November 2026.